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ABSTRACT
The role of an internal medicine physician in the perioperative setting includes the
assessment of peri-operative risk, optimization of modifiable risk factors to decrease
this risk and management of post-operative medical complications that may occur.
Every patient undergoing surgery is at risk for procedural and anesthesia complications,
in addition the patient is at risk of developing adverse medical events. Unlike surgical
risk which is related to the procedure being performed and the risk of anesthesia, the
factors affecting the medical risk are often modifiable. These modifiable risk factors
form the principal basis of risk stratifying patients prior to surgery.
Neurosurgical patients pose certain unique challenges in the peri-operative setting
and the pre-operative assessment forms a starting point in the prevention of not just
post-operative cardiac complications but also thrombotic events and in reducing the
overall morbidity and length of hospital stay.
In this chapter, we summarize our approach to the cardiac risk stratification of patients
undergoing neurosurgery. We review recommendations from accepted guidelines and
provide a step wise approach to the cardiac risk assessment of a patient undergoing
elective surgery.

INTRODUCTION
The medical pre-operative evaluation has primarily comprised of assessing a patient’s
risk of developing major adverse cardiac events in the post-operative period. However,
any patient undergoing surgery is exposed to a risk of several complications affecting
different systems. These include pulmonary, cardiac, thrombotic, bleeding events,
complications from the surgical procedure and anesthesia. The risks associated
with anesthesia and the procedure itself are not modifiable and not discussed in this
chapter. We cover the pre-operative assessment of a patient undergoing neurosurgery
with a focus on cardiac risk assessment. Medical risks are modifiable in many cases and
are affected by a patient’s overall health, nutritional status, comorbid conditions and
baseline activity level. The aim of this article shall be to review the most up-to-date
guidelines and summarize our approach to a risk stratifying a patient undergoing
neurosurgery from a cardiac standpoint.

CARDIAC RISK STRATIFICATION OF NEUROSURGERY PATIENTS
Around 235 million surgeries are performed globally every year.1 Cardiac events are
the leading cause of post-operative complications, 2 the risk of a patient developing
cardiac complications depends on the patient’s baseline risk. This is the principle of
pre-op risk assessment and the aim of the pre-op cardiac assessment is to estimate
this baseline risk and determine if the patient needs additional cardiac testing. The
ACC/AHA guidelines form the cornerstone of pre-op assessment today. Per these
guidelines, the risk stratification approach should consider the type of surgery, the
urgency of the procedure being performed and clinical status of the patient.3 The
guidelines define low risk procedures as those with a <1% risk of major adverse cardiac
events (MACE) based on combined patient and surgical characteristics. Whereas, the

elevated risk group comprises of those
with a ≥ 1% risk of MACE3. The latest ACC/
AHA guidelines, published in 2014, stratify
procedures into these two categories.
The approach to the patient depends on
the category they fall into.
The timing of many neurosurgical procedures is urgent or emergent and this
makes them high risk from the cardiac
standpoint even if the patient has a low
baseline risk. In addition, a large subset
of the neurosurgical patient population is chronically ill and with multiple
comorbid conditions that increases the
risk of surgical complications.4,5

CHOOSING PATIENTS WHO
SHOULD UNDERGO A
PRE-OPERATIVE ASSESSMENT:
In choosing patients who should undergo
a cardiac pre-operative assessment,
certain factors need to be considered.
Urgent and emergent surgery should
not be delayed for a pre-operative
evaluation. In these situations, the risk
of delaying the procedure far outweighs
the potential benefit of identifying
underlying medical or cardiac problems.
As an example, this situation often arises
in neurosurgical patients who present
with intracranial or spine pathology
requiring immediate surgical intervention.
Delaying surgery to assess cardiac risk in
these patients would lead to devastating
consequences.
The guidelines on pre-operative assessment are directed at patients undergoing
elective surgery and do not recommend
delaying surgery for assessment.3,6 These
patients have a higher risk of cardiovascular adverse events even if their baseline
risk level is low, risk indices are based on
data from elective surgeries and are not
accurate in patients undergoing urgent
or emergent procedures and should not
be used for these patients. Whenever
possible, a thorough history and physical
exam should be obtained for all patients.
This should be to look for a history of
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bleeding events, serious drug allergies,
and a history of medical comorbidities
that could complicate the post-operative
course.
For all other patients a step wise approach
to cardiac risk stratification is outlined
below.

Step 1: Is the patient at very high
risk for MACE?

Factor

Points Assigned
#

Ischemic heart disease

1

History of heart failure*

1

History of stroke or transient ischemic attack

1

On insulin for diabetes

1

Serum creatinine (>2.0 mg/dl) pre-operatively

1

This group of patients includes patients
with hemodynamically significant valvular
heart disease, decompensated heart
failure, high grade conduction blocks,
supraventricular tachycardias with
uncontrolled ventricular rate, malignant
arrhythmias, symptomatic bradycardia,
recent MI and unstable angina.7 They
need to be referred to a specialist for
workup and treatment of these conditions and should not undergo elective
surgery without a consultation.

*H
 istory of congestive heart failure, pulmonary edema, radiographic evidence of pulmonary vascular congestion,
paroxysmal dyspnea or physicial exam finding of S3 gallop/bilateral rates.

Step 2: Is the patient at low (<1%)
risk of MACE?

Table 2. Risk Estimates from The Revised Cardiac Risk Index

The next step of the assessment is to use
a risk estimation index to determine if the
patient is at low risk of MACE (<1%). There
are several risk indices and Lee’s Revised
Cardiac Risk Index (RCRI) is one of he
most widely used. Two additional risk
indices based on the National Surgical
Quality Improvement Program NSQIP
may also be used. These are the Gupta
scale and the NSQIP Myocardial Infarction and Cardiac Arrest (NSQIP MICA).
Factors used in calculating the RCRI
score are outlined in Table 1.

RCRI score
(Points)

These scales are used to estimate the
risk of MACE. A ≥1% risk of MACE puts
the patient in the elevated risk category.
Patients who are <1% risk of MACE are
considered low risk and no further
cardiac testing is recommended.3
After the publication of the original RCRI,
many estimates of cardiac events based
on the RCRI points scored have been
published. Pooled risk estimates showed
that the event rates were higher than
the original estimate.6,8 These differences are discussed in the Canadian
Cardiovascular Guidelines published
in 2017 and are attributed to the use of
troponin measurement and inclusion of
emergency surgery patients in the more
recent data.6 We follow the recommendations of the Canadian guidelines in

6

Table 1. Lee's Revised Cardiac Risk Index
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†

High-risk surgery

1

# 

Defined as patient with a history of myocardial infraction (MI), positive exercise stress testing, ongoing chest pain,
presumed to be due to ishemia or use of nitrates or electrocardiogram with Q waves.

†

High risk surgery was defined as intraperitoneal, intrathoracic, suprainguinal vascular procedures.

Modified version of index published by Lee TH et al. Derivation prospective validation of a simple index
for prediction of cardiac risk of major noncardiac surgery. Circulation. 199 Sept 7; 10(10):1043-9

Risk estimate (%) and 95% CI
based on original data*

Risk estimate and 95% CI based
on pooled data3#

0

0.4% [0.05%–1.5%]

3.9% [2.8%–5.4%]

1

0.9% [0.3%–2.1%]

6.0% [4.9%–7.4%]

2

6.6% [3.9%–10.3%]

10.1% [8.1%–12.6%]

≥3

11.0% [5.8%–18.4%]

15.0% [11.1%–20.0%]


* Estimates
from the original published data by Lee TH et al. Derivation and prospective validation of a simple index
for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999 Sep 7; 100(10):1043-9
#

R isk estimates from Duceppe et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk
Assessment and Mamagement for Patients Who Undergo Noncardiac Surgery. These estimates were based on
external validations published after the original study by Lee TH et al (1999).

Table 3. Metabolic Equivalents (METS) of some common activities
Activity

METS

Resting state#

1 MET

Cooking

2-3 METS

Car Driving

2 METS

Walking (3 miles/hr or 5 km/hr)

3 METS

Climb Stairs

4-5 METS

Snow Shoveling

5 METS

Running (8 miles/hr or 13 km/hr)

13 METS

# For a 70 kg individual. Values are approximate values based on data published by Jette et al. in Metabolic
equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity.
Clin Cardiology 1990 Aug;13(8):555-65
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using a RCRI score of ≥1 point and do
not recommend using the estimated
percent risk to classify patients under the
elevated risk category (Table 2).

Step 3: Assess Functional Capacity
Under the AHA guidelines, the next step
in assessing patients under the elevated
risk category is to estimate functional
capacity. Self-reported functional capacity
is the most widely used method of
estimation. The patient is asked what
level of exertion they can tolerate without
experiencing symptoms. Metabolic
equivalents (METS) of many common
activities are outlined in Table 3.
The Duke activity status index (DASI) is
a standardized tool for estimating functional capacity.9 A study comparing the
DASI, self-reported functional capacity
and cardiopulmonary exercise testing
showed that only scores on DASI correlated with cardiac events in the post-op
period.10 Therefore, if functional capacity
is included in the pre-op assessment, it
is recommended that a standardized
estimation tool like the DASI be used.
Per the approach outline in the ACC/AHA
guidelines, patients at elevated risk, tolerating >4 METS without symptoms do not
need additional cardiac testing. Whereas,
patients at elevated risk with an unknown
functional capacity or not able to reach 4
METS require additional cardiac testing.
Various modalities for cardiac testing in
these patients is outlined below.

CARDIAC TESTING
MODALITIES
Stress Testing
The ACC/AHA guidelines recommend
stress testing (exercise or pharmacologic
with dobutamine stress echocardiography (DSE) or myocardial perfusion
imaging (MPI) in patients at elevated
risk for noncardiac surgery and have an
unknown or poor (< 4 METS) functional
capacity if it will change management.3
Routine stress testing just because a
patient is undergoing noncardiac surgery
is not recommended. 11 A stress test
showing a large area of ischemic myocardium or multiple reversible defects on
MPI is associated with a higher incidence
of post-op death from cardiac causes or
non-fatal myocardial infarction.12,13

Additionally, findings from several
single center studies have shown that
a negative stress test has a high negative predictive value. This is useful for
patients who are moderate risk but limits
the utility of stress testing in the highest
risk patients.14,15

Resting Echocardiography:
Echocardiography to assess left ventricular function is recommended if the
patient has dyspnea of unknown etiology,
if they patient has heart failure and there
is a change in their clinical condition or if
a patient with stable heart failure has not
had an echocardiograph in one year.3,16
Echocardiography to assess valvular
function should be performed if a patient
has known valvular disease and presents
with a change clinically or if the patient
presents with clinical signs of moderate
or severe valvular heart disease.3,16
The Canadian guidelines published
in 2017 favor biomarker testing and
recommend a move away from resting
echocardiography for pre-op testing,
this is based on evidence showing that
biomarker testing is superior to echocardiography in predicting adverse
perioperative outcomes.17 It is suggested
that a resting echocardiogram should
not be performed as a substitute to
stress testing or biomarker measurement
for high risk patients. However, resting
echocardiography should be performed
in patients suspected of having systolic
heart failure to evaluate their left
ventricular ejection fraction. It should
also be done in patients with suspected
moderate or severe valvular heart disease
if they have not had an echocardiogram
in the last one year or there has been a
significant change in their clinical status
since the last evaluation.

Role of pre-operative electrocardiography (ECG):
The ACC/AHA guidelines recommend
obtaining an electrocardiogram in
patients undergoing intermediate or
high risk noncardiac surgery if they have
a history of structural heart disease,
arrhythmias, or vascular disease
(includes CAD, stroke, TIA, or peripheral
arterial disease). ECGs are not recommended for low risk surgery. Routine
ECGs based on age cut-offs are also not
recommended. 3,18

The electrocardiogram is often performed
in patients undergoing surgery based on
arbitrary age cut-offs. A resting echocardiogram is useful in the detection of
arrhythmias and to compare to baseline
for patients with known CAD, peripheral
vascular disease, cerebrovascular disease
or ischemic heart disease.19,20 However,
its utility is significantly limited when a
patient’s baseline ECG is unknown or if
nonspecific abnormalities are found on
the ECG. These limitations make it less
useful in diagnosing asymptomatic CAD in
patients undergoing noncardiac surgery.

THE CANADIAN
CARDIOVASCULAR SOCIETY
GUIDELINES
The Canadian guidelines published in 2017
changed long standing recommendations
on cardiac pre-operative evaluation and
advocated a move towards biomarker
measurement and post-operative troponin
level testing.6 We summarize the main
recommendations from the paper below.
• Measurement of biomarkers (proBNP
or NT-proBNP) prior to surgery in
patients who are >65 years of age or
have RCRI ≥ 1 or are 45-64 years old
with cardiac comorbidities.
• Advise against performing resting
echocardiography, coronary computed
tomography angiography, stress testing
or cardiopulmonary exercise testing
or nuclear imaging as a part of perioperative risk assessment.
• Recommend daily troponin measurement for patients with elevated
biomarker (pro-BNP or NT-proBNP)
or if biomarkers are not measured
but they score 1 or more points on
the RCRI scale.
Additionally, The Canadian Cardiovascular Society guidelines recommend
the following for continuing or initiating
medications in the perioperative period.
• Acetylsalicylic Acid (ASA) should not
be continued or initiated for cardiovascular protection or prevention.
Exceptions include patients who had
a recent coronary stent placement or
will undergo carotid endarterectomy
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• Β-blockers or α2-agonist initiation is
not recommended in the 24 hours
prior to surgery.
• Recommends holding angiotensinconverting enzyme inhibitors (ACEI)
and angiotensin II receptor blockers
24 hours prior to surgery.
• If a patient develops myocardial infarct
or injury in the post-operative period,
a statin and ASA should be started.

CONCLUSION
Our article summarizes existing guidelines into a stepwise approach that
provides a picture of our current practice
as a hospitalist group providing perioperative care to neurosurgical patients.
We attempt to highlight appropriate
indications and use criteria for cardiac
testing methods. Neurosurgical patients,
both spine and intracranial can have
high morbidity and need careful perioperative care. Keeping this in mind, it is
even more imperative that appropriate
testing be performed when indicated
and unnecessary testing be avoided.
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